ReviewBritish journal of clinical pharmacology2006
N-acetylcysteine -- passe-partout or much ado about nothing?
Review in British journal of clinical pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 126 citations in OpenAlex.
- Oral administration of γ-glutamylcysteine increases intracellular glutathione levels above homeostasis in a randomised human trial pilot study.Redox biology · 2017Trial
- N-Acetylcysteine inhibits platelet-monocyte conjugation in patients with type 2 diabetes with depleted intraplatelet glutathione: a randomised controlled trial.Diabetologia · 2012Trial
- Lycopene Mitigates Malaria-Induced Reactive Oxygen and Nitrogen Species and Oxidative Damage in Mice Brain and Lungs.Parasite immunology · 2025Article
- Niosomes loading N-acetyl-L-cysteine for cancer treatment in vivo study.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Protective and Regenerative Effects of Reconstituted HDL on Human Rotator Cuff Fibroblasts under Hypoxia: An In Vitro Study.Antioxidants (Basel, Switzerland) · 2024Article
- Mitochondria-Targeted Antioxidant Therapeutics for Traumatic Brain Injury.Antioxidants (Basel, Switzerland) · 2024Review
- How to Increase Cellular Glutathione.Antioxidants (Basel, Switzerland) · 2023Review
- Biological and Genetic Mechanisms of COPD, Its Diagnosis, Treatment, and Relationship with Lung Cancer.Biomedicines · 2023Review
- NAC blocks Cystatin C amyloid complex aggregation in a cell system and in skin of HCCAA patients.Nature communications · 2021Article
- Comprehensive Review of Methodology to Detect Reactive Oxygen Species (ROS) in Mammalian Species and Establish Its Relationship with Antioxidants and Cancer.Antioxidants (Basel, Switzerland) · 2021Review
- Benefits of N-acetylcysteine on liver functions in living donor hepatectomy.Indian journal of anaesthesia · 2020Article
- Enolate-forming compounds provide protection from platinum neurotoxicity.Chemico-biological interactions · 2020Article
- The new HJournal of enzyme inhibition and medicinal chemistry · 2018Article
- N-acetyl-L-cysteine and cysteine increase intracellular calcium concentration in human neutrophils.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2016Article
- Inflammatory and oxidative stress in rotavirus infection.World journal of virology · 2016Review
- Oxidative Stress Attenuates Lipid Synthesis and Increases Mitochondrial Fatty Acid Oxidation in Hepatoma Cells Infected with Hepatitis C Virus.The Journal of biological chemistry · 2016Article
- The 100 most influential publications in paracetamol poisoning treatment: a bibliometric analysis of human studies.SpringerPlus · 2016Article
- Oxidative Stress and Inflammation in Hepatic Diseases: Therapeutic Possibilities of N-Acetylcysteine.International journal of molecular sciences · 2015Review
- The relationship between COPD and lung cancer.Lung cancer (Amsterdam, Netherlands) · 2015Review
- N-acetylcysteine selectively antagonizes the activity of imipenem in Pseudomonas aeruginosa by an OprD-mediated mechanism.Antimicrobial agents and chemotherapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In experimental studies, the old mucolytic agent N-acetylcysteine (NAC) has had beneficial effects in disorders supposedly linked to oxidative stress. Numerous, mainly small clinical trials with variable doses have yielded inconsistent results in a wide variety of diseases. NAC added to the conventional therapy of human immunodeficiency virus infection might be of benefit; in respect of chronic obstructive pulmonary disease, systematic reviews and meta-analyses suggested that prolonged treatment with NAC is efficacious, but a recent multicentre study has questioned this. In a large intervention trial on cancer recurrence, NAC was ineffective. NAC infusions have been widely used in acute hepatic failure but convincing evidence of its benefits is lacking. A preliminary study reported that NAC is effective in preventing radiocontrast-induced nephropathy but thereafter highly mixed results have been published, and even meta-analyses disagree on its efficacy. In intensive care NAC has mostly been a disappointment but recently it has 'given promises' in surgery with cardiopulmonary bypass. NAC therapy is routine only in paracetamol intoxication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.